Results 61 to 70 of about 72,717 (274)

Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis

Cancer Control, 2020
Background: Denosumab is a human monoclonal antibody that has been used successfully in the treatment of giant cell tumors of bone. These tumors are rare and, in principle, benign, but they are highly aggressive, locally advanced, osteolytic bone tumors ...
Josef Yayan MD
doaj   +1 more source

Ivory Osteoma Of Temporal Bone [PDF]

, 2006
Osteomas are slow growing bony tumors common in fronto-ethmoid regions and rare in temporal bone. These are usually asymptomatic and require treatment mainly for cosmetic reasons.
Meher, Dr. Ravi
core   +1 more source

Malignant fibrous histiocytoma with skeletal involvement [PDF]

, 1978
Malignant fibrous histiocytoma of soft part is rather common but malignant fibrous histiocytoma of the bone is rarely encountered clinically. Authors present five cases of malignant fibrous histiocytoma with skeletal involvement and discuss their ...
Taguchi, Kohji, Takechi, Hideo
core   +1 more source

Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone

Nature Communications, 2020
The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration.
P. Lutsik, A. Baude, D. Mancarella, S. Öz, Alexander Kühn, R. Toth, Joschka Hey, U. Toprak, Jinyeong Lim, Viet Ha Nguyen, Chaohui Jiang, A. Mayakonda, M. Hartmann, Felix Rosemann, Kersten Breuer, Dominik Vonficht, F. Grünschläger, Suman Lee, Maren Kirstin Schuhmacher, Denis Kušević, A. Jauch, D. Weichenhan, J. Zustin, M. Schlesner, S. Haas, J. Park, Y. Park, U. Oppermann, A. Jeltsch, F. Haller, J. Fellenberg, Anders M. Lindroth, C. Plass   +32 more
semanticscholar   +1 more source

Odontogenic Myxoma Of The Maxilla: A Clinical Case Report And Review Of Literature [PDF]

, 2013
Odontogenic myxomas are rare benign mesenchymal  tumours of head and neck with a potential for  local infiltration and recurrence. They appear to originate from the dental papilla, follicle or periodontal ligament in mandible and less commonly the ...
Bhardwaj, Vikram, Garg, Bhawna, Munjal, Manish, Sood, Neena   +3 more
core   +2 more sources

Reconstruction of metatarsal bone after giant cell tumor resection with no vascularized fibular graft in a pediatric patient: Case report and review of literature

Frontiers in Pediatrics, 2022
The Giant Cell tumor (GCT) is a benign, locally aggressive lesion that cause bone destruction and shows a malignant potential. It is a relatively common skeletal tumor that is therefore typically seen in young adults.
M. Florio, S. Careri, C. Zoccali, A. G. Aulisa, A. G. Aulisa, F. Falciglia, R. M. Toniolo, M. Giordano   +7 more
doaj   +1 more source

Cytomorphological Diagnosis of Giant Cell Tumour of Distal End Radius in Elderly Patient [PDF]

, 2013
Giant cell tumours (GCTs) of bone have been described as the most challenging benign bone tumors. It is very unusual for GCT to occur in patients younger than 20 yrs or older than 55 years. GCT is seen with a slightly increased frequency in females.
Bagale, P, Dravid, NV, Gadre, AS, Suryawanshi, K, Tayade, Y   +4 more
core   +1 more source

Clinically aggressive central giant cell granulomas in two patients with neurofibromatosis 1 [PDF]

, 2006
Background Neurofibromatosis 1 (NF1) is an autosomal dominantly inherited disorder caused by a spectrum of mutations affecting the Nf1 gene. Affected patients develop benign and malignant tumors at an increased frequency.
Edwards, Paul C., Fantasia, John E, Rosenberg, Tracey J, Ruggiero, Salvatore, Sachs, Stephen A, Saini, Tamjit   +5 more
core   +1 more source

Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review

Diagnostics
Background: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers.
Muhammad Taqi, Haseeb ul Rasool, Mobeen Zaka Haider, Munjed Al Muderis   +3 more
doaj   +1 more source

Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage

Journal of Bone and Joint Surgery. American volume, 2018
Background: Recent clinical studies have suggested that denosumab is associated with tumor response and reduced surgical morbidity in patients with giant-cell tumor of bone (GCTB).
C. Errani, S. Tsukamoto, G. Leone, A. Righi, M. Akahane, Yasuhito Tanaka, D. Donati   +6 more
semanticscholar   +1 more source